Crescent Bio Q3 net loss $24.6M; cash $133.3M; CR-001 IND on track

CRESCENT BIOPHARMA, INC.

Net loss of $24.6M ($1.27 per share) for Q3 2025; R&D expense $20.3M, G&A $5.5M.
Cash position $133.3M as of Sept 30, 2025, expected to fund operations through 2027.
IND submission for CR-001 (PD-1 x VEGF bispecific) on track for Q4 2025; Phase 1 start Q1 2026.
Preclinical data for CR-001 presented at SITC showing cooperative pharmacology and anti-tumor activity.
ADC program CR-002 IND submission expected mid-2026; CR-003 also advancing.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001628280-25-049865
form_type: 8-K
ticker: CBIO
cik: 0001253689
company_name: CRESCENT BIOPHARMA, INC.
filed_at: 2025-11-06T23:59:59+00:00
discovered_at: 2026-05-14T18:02:38.990949+00:00
generated_at: 2026-05-16T23:23:25.409842+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.55
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001628280-25-049865
json_url: https://secwatch.observer/filing/0001628280-25-049865.json
markdown_url: https://secwatch.observer/filing/0001628280-25-049865.md
text_url: https://secwatch.observer/filing/0001628280-25-049865.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1253689/000162828025049865/0001628280-25-049865-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1253689/000162828025049865/cbio-20251106.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001628280-25-049865

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.